<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124249</url>
  </required_header>
  <id_info>
    <org_study_id>CNUH-2021-314</org_study_id>
    <nct_id>NCT05124249</nct_id>
  </id_info>
  <brief_title>Imaging and Physiologic Evaluation of Coronary Artery Disease</brief_title>
  <official_title>Imaging and Physiologic Evaluation of Coronary Artery Disease: a Prospective Registry Study (IP-CAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term clinical outcomes and prognostic factors in patients with coronary&#xD;
      artery disease (CAD) undergoing invasive coronary angiography (ICA), intravascular imaging,&#xD;
      or invasive physiologic assessment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The traditional standard method for evaluating coronary artery disease (CAD) is invasive&#xD;
      coronary angiography (ICA). ICA enables the assessment of anatomic severity of the epicardial&#xD;
      artery and the severity of diameter stenosis can be closely associated with myocardial&#xD;
      ischemia. However, there remains concern that anatomical severity is not always identical&#xD;
      with functional significance. Actually, even the patients showed positive non-invasive tests&#xD;
      including treadmill test, stress echocardiography, coronary computed tomography angiography,&#xD;
      or nuclear imaging, less than half of the patients showed significant stenosis on ICA.&#xD;
      Therefore, the investigators need further investigation to overcome the limitations of ICA.&#xD;
&#xD;
      In this regard, intravascular imaging, such as intravascular ultrasound (IVUS) and optical&#xD;
      coherence tomography (OCT), is a useful tool for assessing the anatomical severity in more&#xD;
      detail. Those imaging modalities produce cross-sectional images of CAD and imaging modalities&#xD;
      are allowing to assess lesion characteristics, plaque morphology, treatment planning, and&#xD;
      optimization of the implanted stent. Furthermore, imaging-guided percutaneous coronary&#xD;
      intervention (PCI) has been shown favorable outcomes, compared with angiography only-guided&#xD;
      PCI, especially in complex lesions. Meanwhile, there has been an ample body of evidence that&#xD;
      invasive coronary physiology assessment, such as fractional flow reserve (FFR), also can be&#xD;
      useful for assessing the functional significance. Therefore, the current guidelines have&#xD;
      continuously recommended intracoronary imaging and invasive physiologic assessment for&#xD;
      guiding the treatment of CAD.&#xD;
&#xD;
      The aim of the IP-CAD (Imaging and Physiologic Evaluation of Coronary Artery Disease: a&#xD;
      Prospective Registry Study) is to evaluate the long-term clinical outcomes according to the&#xD;
      imaging-guided or physiology-guided PCI in real-world practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>a composite of all-cause death, myocardial infarction, or any revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause death</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>death from any-cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiac death</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>death from cardiac-cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of myocardial infarction</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>Myocardial infarction without peri-procedural myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of target lesion revascularization</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>ischemia-driven or all</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of target vessel revascularization</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>ischemia-driven or all</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of any revascularization</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>ischemia-driven or all</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stent thrombosis</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>definite or probable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ischemic or hemorrhagic stroke</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>Ischemic or hemorrhagic stoke by braing imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of BARC type 2,3, or 5 bleeding</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>Bleeding Academic Research Consortium (BARC) type 2,3 or 5 bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>3-Year after the index procedure</time_frame>
    <description>a composite of all-cause death, myocardial infarction, any revascularization, and ischemic or hemorrhagic stroke</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>ICA</arm_group_label>
    <description>Patients who undergoing invasive coronary angiography with intravascular imaging or invasive physiologic assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCI</arm_group_label>
    <description>Patients who undergoing percutaneous coronary intervention with intravascular imaging or invasive physiologic assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment</intervention_name>
    <description>Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment</description>
    <arm_group_label>ICA</arm_group_label>
    <arm_group_label>PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>Patients who undergoing PCI</description>
    <arm_group_label>PCI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        About 2,000 patients with suspected ischemic heart disease and underwent ICA, intravascular&#xD;
        imaging, or invasive physiologic assessment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be at least 18 years of age&#xD;
&#xD;
          -  Subjects who suspected ischemic heart disease and underwent ICA.&#xD;
&#xD;
          -  Subjects who were performed intravascular imaging or invasive physiologic assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with Age &lt;18 years&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Joon LeeHong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Medical School; Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young Joon Hong, MD, PhD</last_name>
    <phone>82-62-220-5778</phone>
    <email>hyj200@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seung Hun Lee, MD, PhD</last_name>
    <phone>82-62-220-4246</phone>
    <email>lsh8602@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Joon Hong, MD, PhD</last_name>
      <phone>82-62-220-5778</phone>
      <email>hyj200@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Seung Hun Lee, MD, PhD</last_name>
      <phone>82-62-220-4246</phone>
      <email>lsh8602@naver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Young Joon Hong, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Young Joon Hong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Intravascular Imaging</keyword>
  <keyword>Intravascular Ultrasound</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Fractional flow reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year after study completion</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT05124249/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

